• AbbVie bags option on Turnstone oncolytic virus candidates fiercebiotech
    October 11, 2017
    AbbVie has secured an option on three of Turnstone Biologics’ oncolytic viral immunotherapies. The deal gives AbbVie the chance to add Turnstone’s lead MAGEA3 candidate to its pipeline once data from two ongoing phase 1/2 trials are available.
PharmaSources Customer Service